295 results about "Virus Protein" patented technology

The invention relates to the technical field of biomedicine, in particular to an anti-influenza A virus NP protein antibody pair and application thereof. The antibody pair comprises two monoclonal antibodies; the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; one monoclonal antibody in the monoclonal antibody pair is named as a 10G10 antibody, and the other monoclonal antibody is named as a 11F8 antibody. The invention also discloses a nucleic acid molecule for coding the monoclonal antibody and a hybridoma cell strain for secreting the monoclonal antibody. In addition, the invention also discloses a kit for detecting influenza virus protein, which comprises the monoclonal antibody pair, the 10G10 antibody is used as a capture antibody, and the 11F8 antibody is used as a labeled antibody. The antibody for resisting the influenza A virus NP protein provided by the invention has relatively good specificity on the influenza virus protein.

The invention discloses a method for improving citrus yellow vein disease resistance by using a ClPsaN gene. The method comprises the following steps: (1) cloning a VIGS fragment of the citrus ClPsaN gene; (2) constructing two VIGS expression vectors of TRV and CLBV; and (3) transforming the citrus by the VIGS expression vector to obtain a citrus ClPsaN gene silenced VIGS plant. According to the invention, the VIGS vector of the Citrus ClPsaN gene is constructed, and then the Citrus is transformed, so that the obtained Citrus plant can show obvious resistance to the Citrus yellow vein clearing virus, the titer of the Citrus yellow vein clearing virus can be reduced by 22-34%, the accumulation amount of the virus protein is reduced by 35-50%, and the attack degree of the Citrus yellow vein clearing virus is obviously reduced; the TRV silencing of the citrus ClPsaN gene does not influence the phenotype of a citrus plant, and the citrus ClPsaN gene can be used as a candidate gene for citrus yellow vein disease resistance breeding together with a plurality of citrus yellow vein disease-resistant and susceptible genes by utilizing the cooperation of VIGS silencing, RNA interference, gene editing and other technologies.

The invention belongs to the field of biological medicine, and particularly relates to a respiratory syncytial virus F protein mutant and application thereof. The respiratory syncytial virus F protein mutant is characterized in that at least one pair of amino acid residues in an F1 subunit and / or an F2 subunit of F protein polypeptide are substituted by cysteine, and / or an F protein signal peptide part is substituted by a human immunoglobulin light chain signal peptide, and / or alanine A at the 107 site of a multi-base sequence is mutated into arginine R, lysine K at the 134 site is mutated into arginine R, and the amino acid residues in the F1 subunit and / or the F2 subunit of the F protein polypeptide are mutated into arginine. According to the invention, more neutralizing antibody epitopes can be exposed, the stable pre-fusion conformation is maintained, effective neutralizing antibody reaction and antibody binding reaction to the RSV subtypes A and B can be ensured, and the vaccine is suitable for various vaccine forms taking the RSV F protein as the antigen.

The invention belongs to the technical field of immunology and in vitro diagnosis, and relates to a monoclonal antibody aiming at bovine nodular skin disease virus (LSDV) L1R protein. According to the invention, the LSDV recombinant L1R protein with deletion of a transmembrane region (182-204aa) is obtained through expression; after a mouse is immunized by the protein, a monoclonal antibody 8D5 which is good in reactivity and specificity and aims at the LSDV L1R protein is screened out; heavy chain and light chain variable region sequences for coding the monoclonal antibody 8D5 are obtained; the monoclonal antibody 8D5 can be subjected to specific reaction with LSDV L1R protein, the recombinant protein L1R can be specifically recognized by bovine LSDV positive serum, meanwhile, the monoclonal antibody 8D5 can be used for establishing an LSDV ELISA antibody detection method, and a foundation is laid for LSDV diagnostic technology and vaccine research and development.

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

The invention relates to the technical field of biological medicines, in particular to a rabies virus G protein mutant as well as a preparation method and application thereof. The rabies virus G protein mutant is obtained by carrying out point mutation on an extracellular domain of G protein, the mutant realizes soluble expression of the extracellular domain of the G protein, can induce generation of a high-titer neutralizing antibody, and has more excellent cellular immunity and antibody immune response compared with commercial human rabies vaccines and canine rabies vaccines; the inoculation frequency is expected to be reduced, the immune procedure is shortened, and the immune dosage is reduced.

The invention relates to a Nipah virus N protein specific monoclonal antibody as well as a preparation method and application thereof. The nipah virus specific monoclonal antibody is prepared by immunizing nipah virus N protein, the amino acid sequence of the nipah virus N protein is as shown in SEQ ID NO.2, the nipah virus N protein is obtained by transcription of a nipah virus N gene, and the nucleotide sequence of the nipah virus N gene is as shown in SEQ ID NO.1. The nipah virus specific monoclonal antibody has the advantages that the nipah virus specific monoclonal antibody is prepared by immunizing the nipah virus N protein; the monoclonal antibody with the nipah virus N protein specificity can be specifically combined with the nipah virus N protein and is high in titer and good in affinity, meanwhile, a detection kit prepared based on the antibody can effectively carry out nipah virus detection, and technical support can be provided for epidemiological monitoring and diagnosis of nipah virus infection.

The invention discloses an application of a POK erythroid myelogenic factor ZBTB7A in resisting hepatitis B virus. Experiments prove that the overexpression of the ZBTB7A can significantly reduce the level of secreted HBV-related virus protein and significantly inhibit HBV transcription and replication, and a new potential target is provided for treatment of hepatitis B. The research prompts that the ZBTB7A can be used as a novel HBV host limiting factor, lays a foundation for developing novel antiviral drugs, provides more effective treatment schemes for clinical treatment, and has wide application prospects and market potential.

The invention belongs to the field of electrochemical detection, and relates to an anthrax virus protein nanopore electrochemical detection analysis device and application thereof. According to the device, nanopores formed by anthrax virus protein are embedded into a membrane, a resin chamber is divided into a cis small chamber and a trans small chamber by the membrane, a buffer solution with specific pH is contained in each chamber, and electrodes are placed in the chambers respectively to form a current loop. In the detection process, the device forms an electric field force by applying voltage to push the amino acid to interact with the nanopore, and acquires a current signal for analysis so as to distinguish the amino acid chiral isomer. The technical problem that the amino acid chiral isomers are difficult to distinguish is solved, a high-sensitivity detection means is provided, and the method has the advantages of being easy and convenient to operate and rapid and accurate in detection.

Polypeptides comprising an extracellular domain of rabies virus G protein are provided. The rabies virus G protein extracellular domain may have a deletion of the fusion ring domain. Further provided are nanoparticle vaccines for rabies virus. Further provided are pharmaceutical compositions, methods of making, and methods of using, such as immunizing a subject to produce a protective immune response against rabies virus.

The invention discloses methanogen lyase with the same protein family annotation as PeiR lyase and application of the methanogen lyase, and the methanogen lyase is obtained through homologous screening of Pfam protein family database annotation based on known PeiR lyase characteristics aiming at methanogen cell wall peptide bonds. The PeiR lyase protein can participate in the biological process of hydrolyzing archaea cell walls, methanogens are effectively killed, methane production is reduced, and the protein homologous with the protein has potential methane reduction potential. According to the invention, by integrating metagenome sequencing data of rumen microorganisms, screening methanogenic bacterium virus protein by using series bioinformatics software, and combining Pfam functional domain annotation to carry out homologous relationship analysis, a series of lyase is finally identified and is successfully expressed in a prokaryotic expression system, and meanwhile, an in-vitro gas production experiment result also shows that the methanogenic bacterium virus protein can be successfully expressed in a prokaryotic expression system. The crude enzyme liquid can significantly reduce the methane generation amount.

The invention belongs to the field of biomedicine, and particularly discloses a nasal spray influenza vaccine as well as a preparation method and application thereof. The invention provides a nasal spray influenza vaccine. Fusion protein in the nasal spray influenza vaccine comprises influenza virus strain HA protein or fragments thereof, influenza virus protein epitopes and ferritin. The adjuvant may be a CpG1009 adjuvant to enhance humoral and cellular immunity. A vaccine composed of the fusion protein and a novel CpG adjuvant can induce generation of a strong challenge protection effect.

The invention relates to an anthrax virus protein nanopore buffer solution system and biomolecule detection application, and belongs to the field of nanopore electrochemistry. The invention aims to solve the problem that an anthrax virus protein nanopore is unstable in electrochemical detection, and provides an anthrax virus protein nanopore buffer solution system and application thereof. The buffer solution is composed of trihydroxymethyl aminomethane and a compound I composed of specific cations and anions, the compound I comprises the cations such as NH4 < + >, K < + >, Li < + > and Mg < 2 + > and the anions such as Cl <->, HCOO <-> and SO4 < 2->, and the stability of nanopores is achieved by optimizing the concentration and the pH value. The method is applied to high-sensitivity and high-selectivity detection of different charged small molecules. According to the technical scheme, the stability of the anthrax virus protein nanopore is remarkably improved, the application prospect of the anthrax virus protein nanopore in the field of single molecule detection is widened, and a new thought and method are provided for development of a nanopore sensing technology.

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.

The invention belongs to the technical field of antibodies, and discloses a monoclonal antibody for recognizing EB (Epstein-Barr) virus gp350 protein and application of the monoclonal antibody. The invention provides an anti-EB virus gp350 protein monoclonal antibody or an antigen binding fragment thereof, the anti-EB virus gp350 protein monoclonal antibody comprises 1A12 and 2E4, the 1A12 has high affinity for the gp350 protein (KD (M) = 3.415 E-10), the 2E4 has high affinity for the gp350 protein (KD (M) = 4.851 E-9), the two monoclonal antibodies or the antigen binding fragments thereof can significantly inhibit infection of EBV on epithelial cells and B cells, and the anti-EB virus gp350 protein monoclonal antibody or the antigen binding fragment thereof can be used for preparing anti-EB virus gp350 protein anti-EB virus gp350 protein anti-EB virus gp350 protein anti-EB virus gp350 protein anti-EB virus gp350 protein anti-EB virus. The kit can be used for detecting the existence or level of the gp350 protein in a sample, detecting EB virus, diagnosing diseases caused by EB virus infection, preventing EB virus infection and / or treating and / or preventing diseases caused by EB virus infection.

The invention provides a method for removing capsicum light mottle viruses in capsicum seeds. The method comprises the following steps: (1) carrying out protease hydrolysis treatment on the capsicum seeds by adopting a protease aqueous solution capable of hydrolyzing virus protein shells; and (2) the pepper seeds treated in the step (1) are subjected to light irradiation in a solution containing a photosensitizer to excite the photosensitizer, so that the pepper seeds without the pepper mild mottle viruses are obtained, and the photosensitizer is a visible light excited photosensitizer. Compared with an existing PMMoV virus resisting method, the virus removing method has the advantages that PMMoV viruses of the pepper seeds can be effectively removed, the germination potential and the germination rate of the pepper seeds are not reduced, and the method is more efficient, economical, environmentally friendly and convenient to popularize; the method can promote the prevention and control of pepper virus diseases and the breeding of virus-free pepper seedlings, and guarantee the long-distance transportation of seeds.

The invention provides a prefusion conformational variant of lasa virus GPC protein, which is characterized in that on the basis of a wild type, an S1P site between GP1 and GP2 is replaced by a flexible connecting peptide, proline mutation is introduced to a loose region with unstable conformation in GP2, and a trimeric motif T4 fib is added to the C-terminal of GP2, so that the prefusion conformational variant of the lasa virus GPC protein is obtained. The trimer of the prefusion conformation variant of the lassa virus GPC protein retains important neutralizing antibody epitopes of prefusion conformation, can induce efficient and long-term humoral immune and cellular immune responses, and protects mice from lassa pseudovirus infection. The invention also provides application of the prefusion conformational variant of the lasa virus GPC protein in preparation of drugs or vaccines for treating and preventing lasa fever.

The invention provides a respiratory syncytial virus (RSV) F protein comprising at least one modification or mutation selected from the group consisting of: (1) introducing one or more amino acid mutations into the RSV F protein for filling a hydrophobic cavity; (2) introducing one or more amino acid mutations for electrostatic modification into the RSV F protein; and (3) removing a p27 peptide fragment in the RSV F protein. As a recombinant protein antigen, the RSV F protein is high in stability and easy to store and transport, the expression quantity is increased, the yield is easy to increase, and the modified RSV F protein is higher in immunogenicity and can generate a better immune protection effect.

The embodiment of the invention provides a human and virus protein interaction recognition method based on deep learning. The method is applied to the field of protein interaction recognition, and comprises the following steps: acquiring a human protein data set and a virus protein data set, and preprocessing the human protein data set and the virus protein data set; constructing a double-blind data set and a node degree balance data set according to the preprocessed human protein data set and virus protein data set; constructing a human and virus protein interaction prediction model based on a pre-trained protein language model, and performing training optimization on the human and virus protein interaction prediction model according to the double-blind data set, the node degree balance data set and a preset optimization target; and inputting to-be-processed human protein data and virus protein data into the trained and optimized human and virus protein interaction prediction model for analysis and processing to obtain a human and virus protein interaction recognition result, so that the accuracy and reliability of the recognition result are improved.

The invention belongs to the field of biomedicine, and particularly discloses an influenza nanoparticle vaccine as well as a preparation method and application thereof. The fusion protein containing the influenza virus strain HA protein or the fragment thereof, the influenza virus protein epitope and the ferritin can be used as an antigen to induce an immune response effect aiming at influenza viruses, and a vaccine formed by matching the fusion protein with an MF59 adjuvant can be used for inducing to generate a relatively strong challenge protection effect and has a relatively good cross protection effect.

The invention discloses an application of bortezomib in preparation of a medicine for resisting grouper iridovirus. Researches show that bortezomib has a remarkable inhibiting effect on grouper iridovirus, and is low in cytotoxicity and good in safety. The bortezomib can obviously reduce the fluorescence signal intensity of virus protein, inhibit the transcriptional level of main capsid protein MCP and envelope protein VP19 of the virus and reduce the copy number of DNA and mRNA of the virus; the bortezomib can effectively inhibit grouper iridovirus infection and effectively block synthesis of virus protein, so that efficient inhibition of grouper iridovirus infection is achieved, and along with prolonging of virus infection time, bortezomib can also remarkably inhibit virus gene transcription, protein synthesis and genome replication. Therefore, bortezomib not only can effectively prevent and treat grouper iridovirus infection, but also has the characteristics of high specificity, low toxicity, remarkable antiviral effect and the like, and also has important application value in prevention and control of iridovirus-related diseases in aquaculture industry.

The invention discloses a paralichthys olivaceus rhabdovirus G protein tandem antigen epitope peptide and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO: 1. The preparation method comprises the following steps: (1) firstly, analyzing structural characteristics of HIRRV-G protein, predicting B cell antigen epitopes of the HIRRV-G protein, screening the antigen epitopes with advantages on the basis of a prediction result, and synthesizing the antigen epitopes; (2) screening a candidate peptide fragment with high affinity through an enzyme-linked immunosorbent assay; and (3) sequentially connecting the high-affinity peptide fragment sequences meeting the requirements by using a GPGPG connexon, cloning the connected sequences into a pET-28a prokaryotic expression vector, and performing induced expression to obtain the tandem antigen epitope peptide. Compared with a full-length G protein, the tandem antigen epitope peptide is smaller in molecular weight, higher in stability and higher in hydrophilicity; a large number of specific antibodies can be induced in fish bodies, and the death rate of the paralichthys olivaceus infected by viruses is remarkably reduced. The method can be used for HIRRV diagnosis detection reagent and subunit vaccine development.

The invention relates to the technical field of biological medicines, and particularly discloses mRNA based on a fish nervous necrosis virus CP protein gene, a vaccine and a preparation method and application of the mRNA. The invention provides mRNA (messenger Ribonucleic Acid) of a fish nervous necrosis virus, which has a nucleotide sequence as shown in SEQ ID NO: 1 and structurally comprises a 5'end untranslated region, a signal peptide sequence, an NNV (Neuronecrosis Virus) antigen coding region, a 3 'end untranslated region and polyA. The mRNA vaccine contains an ORF sequence of a capsid protein CP gene capable of resisting NNV virus infection. Animal safety test results of the fish nervous necrosis virus mRNA vaccine prepared by the invention show that the vaccine is safe, effective and convenient and simple in clinical use, and has a wide application prospect in the aspect of prevention and control of viral nervous necrosis of mariculture fishes.

The present invention relates to a nanobody against human adenovirus type 4 Hexon protein, which nanobody has a unique CDR region, can bind to adenovirus type 4 Hexon protein with high affinity, and can neutralize adenovirus type 4 pseudovirus with high neutralizing activity in a virus neutralization test, and to the use thereof in antiviral therapy. The invention also provides application of the nano antibody in preparation of a medicine for treating and / or preventing human type 4 adenovirus infectious diseases and a diagnostic kit.

The invention provides a subunit vaccine composition for porcine epidemic diarrhea, porcine delta coronal and porcine rotavirus as well as a preparation method and application of the subunit vaccine composition, and is characterized in that the subunit vaccine composition comprises prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein, viral subunit protein and pharmaceutically acceptable adjuvants; wherein the amino acid sequence of the prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein is as shown in SEQ No.1, and the viral subunit protein is selected from one or more of porcine epidemic diarrhea virus S protein, porcine delta coronavirus S protein and porcine rotavirus VP8 protein. The vaccine composition disclosed by the invention has the advantages of strong immunogenicity, good safety, no immune interference, high neutralizing antibody titer and long antibody duration.

The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.

The application discloses a method for creating a new strain of Carassius auratus gibelii with resistance to Cyprinid herpesvirus 2 (CyHV2) infection, and the method is characterized in that a gene editing technology is used to target knockout gsdf-a a gene and gsdf-b a gene, and an experimental animal infection model of a homozygous knockout strain of the gene obtained by the technology is established. gsdf Results of the experimental animal infection model show that gsdf the CyHV2 infection resistance of the CyHV2 gene knockout Carassius auratus gibelii is significantly enhanced, the histopathological damage of the Carassius auratus gibelii after being infected with the virus is reduced, the expression of a virus protein ORF47 in liver tissue of the Carassius auratus gibelii is reduced, and the transcription level of a virus gene orf46r is significantly reduced. The new strain of Carassius auratus gibelii created by the method can avoid exogenous gene pollution, and has the advantages that the CyHV2 infection resistance of the Carassius auratus gibelii is significantly enhanced.

The present invention discloses a monoclonal nano antibody for recognizing Epstein-Barr virus gp42 protein, its application and monoclonal nano antibody library, and relates to the technical field of phage display of nano antibodies. The monoclonal nano antibodies EBV-gp42-1023, EBV-gp42-1024 or EBV-gp42-1025 provided by the present invention, and related biomaterials, pharmaceutical compositions or detection products, have very high affinity and specificity for Epstein-Barr virus gp42 protein, and can be widely used in detecting the expression of Epstein-Barr virus gp42 protein, or detecting the occurrence and development process of Epstein-Barr virus-induced tumors, or evaluating the efficacy of drugs for treating Epstein-Barr virus-induced tumors, or treating Epstein-Barr virus-induced tumors.

The invention refers to the use of PAP-I, a plant ribosome inactivating protein (RIP), or a functional variant thereof for treatment of human papillomavirus (HPV) infection and preventing or treating diseases or conditions associated with HPV infection.

This invention discloses a polypeptide that specifically binds to the coronavirus S protein, its encoding gene, and its applications, belonging to the field of molecular biology. The polypeptide specifically binding to the coronavirus S protein provided by this invention contains the following amino acid sequence: HFVKTPARWAWG, obtained through screening using phage display technology. The polypeptide provided by this invention can specifically bind to the coronavirus S protein and specifically block the binding of the coronavirus S protein to ACE2, thereby inhibiting coronavirus infection and can be used to prepare anti-coronavirus drugs.